243 related articles for article (PubMed ID: 20942634)
1. Latest developments in targeted therapy for hepatocellular carcinoma.
Montella L; Addeo R; Caraglia M; Del Prete S
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1635-46. PubMed ID: 20942634
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy of hepatocellular carcinoma: present and future.
Chan SL; Yeo W
J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
[TBL] [Abstract][Full Text] [Related]
4. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Curtit E; Thiery-Vuillemin A; Nguyen T; Heyd B; Pivot X; Di Martino V; Borg C
J Clin Oncol; 2011 Apr; 29(12):e330-2. PubMed ID: 21263091
[No Abstract] [Full Text] [Related]
5. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
6. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang A; Graeven U
Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
[No Abstract] [Full Text] [Related]
7. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
8. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
Zhu AX
Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
[No Abstract] [Full Text] [Related]
9. [Hepatocellular carcinoma].
Kondo S; Ueno H; Morizane C; Okusaka T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
O'Neil BH; Venook AP
Oncologist; 2007 Dec; 12(12):1425-32. PubMed ID: 18165619
[TBL] [Abstract][Full Text] [Related]
11. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
Kudo M
Dig Dis; 2011; 29(3):289-302. PubMed ID: 21829020
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies for hepatocellular carcinoma.
Skelton MR; O'Neil B
Clin Adv Hematol Oncol; 2008 Mar; 6(3):209-18. PubMed ID: 18391920
[TBL] [Abstract][Full Text] [Related]
13. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
Rimassa L; Santoro A
Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
[TBL] [Abstract][Full Text] [Related]
14. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
15. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors to treat liver cancer.
Huynh H
Expert Opin Emerg Drugs; 2010 Mar; 15(1):13-26. PubMed ID: 20128706
[TBL] [Abstract][Full Text] [Related]
17. Novel inhibitors in development for hepatocellular carcinoma.
Wörns MA; Galle PR
Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
[TBL] [Abstract][Full Text] [Related]
18. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
Cheng AL; Shen YC; Zhu AX
Oncology; 2011; 81(5-6):372-80. PubMed ID: 22269894
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeted therapies in hepatocellular carcinoma.
Tanaka S; Arii S
Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]